Article: Defeating COVID-19: The science behind a new ELISA
Posted: 6 April 2021 | Bethyl Laboratories | No comments yet
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
The recent and rapid spread of the novel coronavirus, SARS-CoV-2, has necessitated the development of new assays that are capable of detecting the presence of this virus in patient samples or evidence of recent infection. One strategy being developed are assays to detect the presence of anti-SARS-CoV-2 antibodies in patient sera. Learn how Bethyl’s new ELISAs for COVID-19 seroconversion detection can accelerate discovery through improving the understanding of the virus and immune response to facilitate vaccine breakthroughs and epidemiological studies.
Related content from this organisation
Related topics
Antibodies, Assays, Bioengineering, Biomarkers, Biopharmaceuticals, Cell Cultures, Disease Research, Genome Editing, Immunology, Lab Automation, Mass Spectrometry, Microscopy, Personalised Medicine, Proteomics, Screening, Sequencing, Stem Cells, Targets, Toxicology
Related organisations
Bethyl Laboratories
